MODERN APPROACH ТО DIAGNOSTCS AND TREATMENT OF PATHOLOGICAL HYPERPROLACTINEMIA
Abstract
Hyperprolactinemia is one of the most frequent neuroendocrinal disorders and consequently questions of diagnostics and treatment of this syndrome continue to remain actual. Diagnostics of hyperprolactinemia is not the simple task demanding not only determination of the prolactin levels, but also measurement of its fractions with an assessment of the bioactive prolactin levels, careful studying of the anamnesis, an exception of various somatic, endocrine and neuroendocrinal disturbances. Treatment of a pathological hyperprolactinemia demands the differentiated approach taking into account clinical and biochemical data and radiological data. A leading method of treatment is medical therapy by agonists of dopamin receptors. Diagnostics and treatment of hyperprolactinemia must be based on modern evidence-based guidelines.
About the Author
I. A. Ilovayskaya
Moscow Regional Research and Clinical Institute named by M.F. Vladimirsky
Russian Federation
Russian Federation
References
1. Астафьева Л.И. Клинико-морфологические особенности и результаты медикаментозного и хирургического методов лечения пролактин-секретирующих макроаденом гипофиза: автореф. дис.... докт. мед. наук. — М., 2012. — 40 с.
2. Гиперпролактинемия. Современные подходы и старые проблемы / И.И. Дедов [и др.] // Вестник репродуктивного здоровья. — 2009. — № 2 (июнь). — С. 2 — 8.
3. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Классификация, патогенез, клиника синдрома гиперпролактинемии: Синдром гиперпролактинемии. — М. — Тверь: ООО «Триада», 2004. — С. 121 — 185.
4. Диагностика и терапия умеренных форм гиперпролактинемии / И.А. Иловайская [и др.] // Акушерство и гинекология. — 2000. — № 4. — C. 19 — 22.
5. Иловайская И.А., Марова Е.И. Биология пролактина. Молекулярные формы пролактина // Акушерство и гинекология. — 2000. — № 6. — С. 3 — 6.
6. Иловайская И.А., Марова Е.И. Биология пролактина. Нейроэндокринный контроль и регуляция секреции // Акушерство и гинекология. — 2000. — № 5. — С. 42 — 45.
7. Иловайская И.А., Молитвословова Н.Н., Марова Е.И. Пролонгированный агонист дофамина каберголин в лечении нейроэндокринных заболеваний // Клиническая фармакология и фармакотерапия. — 2002. — № 2. — С. 90 — 93.
8. Клинические и лабораторные аспекты феномен макропролактинемии / Г.А. Мельниченко [и др.] // Вестник Российской академии медицинских наук. — 2007. — № 3. — С. 52 — 54.
9. Результаты длительного наблюдения за больными с умеренной гиперпролактинемией / Г.А. Мельниченко [и др.] // Проблемы эндокринологии. — 2002. — Т. 48, № 3. — С. 18 — 21.
10. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea / J. Webster [et al.] // N. Engl. J. Med. — 1994. — Vol. 331. — P. 904 — 909.
11. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas / C.L. Boguszewski [et al.] // Pituitary. — 2012. — Vol. 15, N 1. — P. 44 — 49.
12. Advances in the treatment of prolactinomas / M.P. Gillam [et al.] // Endocr. Rev. — 2006. — Vol. 27. — P. 485 — 534.
13. Alfonso A., Rieniets K.I., Vigersky R.A. Incidence and clinical significance of elevated macroprolactin levels in patients with hyperprolactinemia // Endocr Pract. — 2006. — Vol. 12, N 3. — C. 275 — 280.
14. Bone density in women with prolactinoma treated with dopamine agonists / E.C. Naliato [et al.] // Pituitary. — 2008. — Vol. 11, N 1. — P. 21—28.
15. Bromocriptine or cabergoline induced pituitary apoplexy: Rare but life-threatening catastrophe / P. Singh [et al.] // J. Hum. Reprod. Sci. — 2011. — Vol. 4, N 1. — P. 59.
16. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis / V. dos Santos Nunes [et al.] // Pituitary. — 2011. — Vol. 14, N 3. — P. 259 — 265.
17. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline / S. Melmed [et al.] // J. Clin. Endocrinol. Metab. — 2011. — Vol. 96, N 2. — P. 273 — 288.
18. Do the limits of serum prolactin in disconnection hyperprolactinaemia need redefinition? A study of 226 patients with histologically verified nonfunctioning pituitary macroadenoma / N. Karavitaki [et al.] // Clin. Endocrinol (Oxf.). — 2006. — Vol. 65. — P. 524 — 529.
19. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature / G. Stalldecker [et al.] // Pituitary. — 2010. — Vol. 13, N 4. — P. 345 — 350.
20. Fernandez A., Karavitaki N., Wass J.A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK) // Clin. Endocrinol (Oxf.). — 2010. — Vol. 72. — P. 377 — 382.
21. Frantz A.G., Kleinberg D.L. Prolactin: evidence that it is separate, from growth hormone in human blood // Science. — 1970. — Vol. 13, N 170 (3959). — P. 745 — 747.
22. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of ‘hook effect' / M. Fleseriu [et al.] // J. Neurooncol. — 2006. — Vol. 79, N 1. — P. 41—43.
23. Gibney J., Smith T.P., McKenna T.J. The impact on clinical practice of routine screening for macroprolactin // J. Clin. Endocrinol. Metab. — 2005. — Vol. 90. — P. 3927 — 3932.
24. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas / F.F. Casanueva [et al.] // Clin. Endocrinol (Oxf.). — 2006. — Vol. 65. — P. 265 — 273.
25. High prevalence of pituitary adenomas: a crosssectional study in the province of Liege, Belgium / A.F. Daly [et al.] // J. Clin. Endocrinol. Metab. — 2006. — Vol. 91. — P. 4769 — 4775.
26. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas / G. Mazziotti [et al.] // Pituitary. — 2011. — Vol. 14, N 4. — P. 299 — 306.
27. Holley J.L. The hypothalamic-pituitary axis in men and women with chronic kidney disease // Adv. Chronic Kidney Dis. — 2004. — Vol. 11, N 4. — P. 337 — 341.
28. Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay / A. Glezer [et al.] // J. Clin. Endocrinol. Metab. — 2006. — Vol. 91. — P. 1048—1055.
29. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas / M. Ono [et al.] // J. Clin. Endocrinol. Metab. — 2010. — Vol. 95, N 6. — P. 2672 — 2679.
30. Is pregnancy the best treatment for perprolactinaemia? / P.G. Crosignani [et al.] // Hum Reprod. — 1989. — Vol. 4, N 8. — P. 910 — 912.
31. Klibanski A. Clinical practice. Prolactinomas // N. Engl. J. Med. — 2010. — Vol. 362. — P. 1219 — 1226.
32. Long-term follow-up of patients with hyper-prolactinaemia / W.J. Jeffcoate // Clin. Endocrinol (Oxf.). — 1996. — Vol. 45, N 3. — P. 299 — 303.
33. Lu C.C., Hsieh C.J. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients // Kaohsiung J. Med. Sci. — 2012. — Vol. 28, N 2. — P. 94 — 99.
34. Martin N.M., Tan T., Meeran K. Dopamine agonists and hyperprolactinaemia // BMJ. — 2009. — Mar 3. — Vol. 338. — P. 381.
35. McKenna T.J. Should macroprolactin be measured in all hyperprolactinaemic sera? // Clin. Endocrinol (Oxf.). — 2009. — Vol. 71. — P. 466 — 469.
36. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women / M. Lebbe [et al.] // Clin. Endocrinol (Oxf.). — 2010. — Vol. 73, N 2. — P. 236 — 242.
37. Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment / H. Dinç [et al.] // Acta Radiol. — 1998. — Vol. 39, N 1. — P. 64 — 69.
38. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy / A. Colao [et al.] // Clin. Endocrinol (Oxf.). — 2007. — Vol. 67, N 3. — P. 426 — 433.
39. Radiotherapy for prolactin-secreting pituitary tumors / L.J. Sheplan Olsen [et al.] // Pituitary. — 2011. — Sep. 27, 16 2011, DOI: 10.1007/s11102-011-0348-6
40. Rains C.P., Bryson H.M., Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation // Drugs. — 1995. — Vol. 49, N 2. — P. 255 — 279.
41. Recent clinical aspects of hyperprolactinemia induced by antipsychotics / W. Milano [et al.] // Rev. Recent. Clin. Trials. — 2011. — Vol. 6, N 1. — P. 52 — 63.
42. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma / T.M. Barber [et al.] // Clin. Endocrinol (Oxf). — 2011. — Vol. 75, N 6. — P. 819 — 824.
43. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy / A. di Sarno [et al.] // J. Clin. Endocrinol. Metab. — 2001. — Vol. 86, N 11. — P. 5256 — 5261.
44. Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging / A.D. Elster [et al.] // Radiology. — 1991. — Vol. 181, N 2. — P. 531—535.
45. Temozolomide in the management of dopamine agonist-resistant prolactinomas / B.C. Whitelaw [et al.] // Clin. Endocrinol (Oxf.). — 2012. — Vol. 76, N 6. — P. 877 — 886.
46. The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism / Z. Hekimsoy [et al.] // Endocr. J. — 2010. — Vol. 57, N 12. — P. 1011 — 1015.
47. Vertebral fractures in males with prolactinoma / G. Mazziotti [et al.] // Endocrine. — 2011. — Vol. 39, N 3. — P. 288 — 293.
48. Watt A., Pobereskin L., Vaidya B. Pituitary apoplexy within a macroprolactinoma // Nat. Clin. Pract. Endocrinol. Metab. — 2008. — Vol. 4, N 11. — P. 635 — 641.
Review
For citations:
Ilovayskaya I.A. MODERN APPROACH ТО DIAGNOSTCS AND TREATMENT OF PATHOLOGICAL HYPERPROLACTINEMIA. Acta Biomedica Scientifica. 2012;(3(1)):127-134. (In Russ.)
Views:
460
.png)
Email this article 
